89Sr治疗多发性骨转移癌的疗效观察(2)
第1页 |
参见附件。
[1]中华人民共和国卫生部医政司,主编.核医学诊断与治疗规范[M].第1版.北京:科学出版社,1997:293-295.
[2]Liepe K, Kotzerke J. Internal radiotherapy of painful bone metastases[J].Methods, 2011, 55(3):258-270.
[3]Utsu Y, Aotsuka N, Masuda S, et al. Atypical onset of therapy-related acute promyelocytic leukemia after combined modality therapy including (89) Sr for metastatic breast cancer[J]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2013, 54(8): 759-763.
[4] Torres Martin de Rosales R, Finucane C, Foster J, et al. 188Re (CO) 3-dipicolylamine-alendronate: a new bisphosphonate conjugate for the radiotherapy of bone metastases[J]. Bioconjugate chemistry, 2010, 21(5): 811-815.
[5] Valkenburg K C, Steensma M R, Williams B O, et al. Skeletal metastasis: treatments, mouse models, and the Wnt signaling[J]. Chinese journal of cancer, 2013, 32(7): 380.
[6] Kurosaka S, Satoh T, Chow E, et al. EORTC QLQ-BM22 and QLQ-C30 quality of life scores in patients with painful bone metastases of prostate cancer treated with strontium-89 radionuclide therapy[J]. Annals of nuclear medicine, 2012, 26(6): 485-491.
编辑/孙杰
您现在查看是摘要介绍页,详见PDF附件。